Lawrence Hamel - ACRX Old Chief Devel. Officer
| ACRXDelisted Stock | USD 1.01 0.01 1.00% |
Executive
Mr. Lawrence G. Hamel is the Chief Development Officer of AcelRx Pharmaceuticals Inc., since September 2006. From 1986 until September 2006, Mr. Hamel has served as our Chief Development Officer since September 2006. From 1986 until September 2006, Mr. Hamel served as Product Development Manager, Director Project Management, Executive Director Oral Product Development, and Vice President Oral Products Development at ALZA Corporationrationration. From 1977 until 1985, Mr. Hamel held a number of other positions at ALZA Corporationrationration, including Senior Chemist, Research Scientist, and Senior Research Fellow since 2006.
| Age | 72 |
| Tenure | 19 years |
| Phone | 650 216 3500 |
| Web | https://www.acelrx.com |
ACRX Old Management Efficiency
The company has return on total asset (ROA) of (0.3222) % which means that it has lost $0.3222 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5112) %, meaning that it created substantial loss on money invested by shareholders. ACRX Old's management efficiency ratios could be used to measure how well ACRX Old manages its routine affairs as well as how well it operates its assets and liabilities.ACRX Old currently holds 10.42 M in liabilities with Debt to Equity (D/E) ratio of 0.43, which is about average as compared to similar companies. ACRX Old has a current ratio of 1.77, which is within standard range for the sector. Note, when we think about ACRX Old's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Gene Esq | Shuttle Pharmaceuticals | N/A | |
| Kara Morley | Lifecore Biomedical | N/A | |
| Pranav Mehta | Amneal Pharmaceuticals, Class | ||
| Ernest Toth | Aquestive Therapeutics | 66 | |
| Sherry Korczynski | Aquestive Therapeutics | N/A | |
| Timothy CPA | Shuttle Pharmaceuticals | 66 | |
| Bill Iskos | Assertio Therapeutics | N/A | |
| John Sadler | Tilray Inc | N/A | |
| Berrin Noorata | Tilray Inc | N/A | |
| Matt Augustson | Lifecore Biomedical | N/A | |
| Marilyn Carlson | Evoke Pharma | 76 | |
| Gregory Sgammato | Amneal Pharmaceuticals, Class | N/A | |
| MBA MD | Aquestive Therapeutics | 68 | |
| Brikkelle Thompson | Lifecore Biomedical | N/A | |
| Thomas Pearl | Organogenesis Holdings | N/A | |
| Robert Cavorsi | Organogenesis Holdings | 46 | |
| Nyree Pinto | Tilray Inc | N/A | |
| Jeff Christensen | Assertio Therapeutics | N/A | |
| Roger Savell | Tilray Inc | 63 | |
| Mary Pietryga | Assertio Therapeutics | N/A | |
| Kenneth Marshall | Aquestive Therapeutics | 65 | |
Management Performance
| Return On Equity | -0.51 | |||
| Return On Asset | -0.32 |
ACRX Old Leadership Team
Elected by the shareholders, the ACRX Old's board of directors comprises two types of representatives: ACRX Old inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ACRX. The board's role is to monitor ACRX Old's management team and ensure that shareholders' interests are well served. ACRX Old's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ACRX Old's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vincent Angotti, CEO, Interim CFO | ||
| Anil Dasu, Chief Officer | ||
| Lawrence Hamel, Chief Devel. Officer | ||
| Pamela MD, Chief CoFounder | ||
| Raffi Asadorian, Chief Officer |
ACRX Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ACRX Old a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.51 | |||
| Return On Asset | -0.32 | |||
| Operating Margin | (28.28) % | |||
| Current Valuation | 3.25 M | |||
| Shares Outstanding | 16.95 M | |||
| Shares Owned By Insiders | 2.63 % | |||
| Shares Owned By Institutions | 38.88 % | |||
| Number Of Shares Shorted | 508.11 K | |||
| Price To Earning | 0.39 X | |||
| Price To Book | 0.74 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Consideration for investing in ACRX Stock
If you are still planning to invest in ACRX Old check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ACRX Old's history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |